Table 1 Characteristics of included studies
Authors | Publication year | Country | Sample size (severe/non-severe) | Study designa | Patients (severe/non-severe) | Age group (severe vs non-severe) | Quality assessment (score) | References |
|---|---|---|---|---|---|---|---|---|
Cai et al. | 2020 | China | 58/240 | Cross-sectional | Severe/non-severe | 64 ± 7.41, 40 ± 18.53 | 8 | [12] |
Cao (Min) et al. | 2020 | China | 19/179 | Single-center cohort | ICU/Non-ICU | 63.7 ± 16.8, 48.6 ± 15.6 | 7 | [13] |
Cao (Weiliang) et al. | 2020 | China | 21/107 | Retrospective study | Severe/non-severe | NR | 4 | [14] |
Deng (a) et al. | 2020 | China | 59/10 | Cross-sectional | Severe/ordinary | 61.4 ± 16.7 (all patients) | 4 | [7] |
Deng (b) et al. | 2020 | China | 36/9 | Cross-sectional | ICU/ordinary cases | 61.4 ± 16.7 (all patients) | 4 | [7] |
Guan et al. | 2020 | China | 173/926 | Cohort | Severe/non-severe | 52 ± 18.53, 45 ± 17.05 | 6 | [20] |
Huang et al. | 2020 | China | 13/28 | Cohort | ICU/Non-ICU | 49 ± 14.82, 49 ± 12.23 | 5 | [7] |
Jian-ya et al. | 2020 | China | 7/44 | Retrospective, single-center case series | Severe/non-severe | 52 ± 11.86, 44 ± 11.86 | 3 | [21] |
Li et al. | 2020 | China | 25/58 | Retrospective study | Severe or critical/ordinary group | 53.7 ± 12.3, 41.9 ± 10.6 | 5 | [25] |
Liu (Jingyuan) et al. | 2020 | China | 17/44 | Prospective single-center study | Severe or critical/common type | 56 ± 9.75, 41 ± 18.75 | 5 | [23] |
Liu (Songqiao) (a) et al. | 2020 | China | 53/97 | Retrospective multicenter cohort study | Severe or critical/asymptomatic or Mild | 60.09 ± 13.86, 35.96 ± 19.88 | 9 | [20] |
Liu(Songqiao) (b) et al. | 2020 | China | 27/470 | Retrospective multicenter cohort study | Severe or critical/moderate | 60.09 ± 13.86, 44.47 ± 15.62 | 9 | [20] |
Liu (Yanli) et al. | 2020 | China | 26/56 | Retrospective study | ARDS/Non-ARDS | 61 ± 13.34, 49 ± 13.34 | 8 | [24] |
Wang et al. | 2020 | China | 36/102 | Retrospective, single-center case series (cohort) | ICU/Non-ICU | 66 ± 15.57, 51 ± 18.53 | 7 | [25] |
Young et al. | 2020 | Singapore | 6/12 | Descriptive case series | Required supplemental O2/Did not require supplemental O2 | 56 ± 6.5, 37 ± 6.25 | 6 | [27] |
Zhang (Fengqin) (a) et al. | 2020 | China | 9/23 | Retrospective single center | Critical/common | 50.3 ± 14, 40.8 ± 12.2 | 6 | [23] |
Zhang (Fengqin) (b) et al. | 2020 | China | 26/23 | Retrospective single center | Severe/common | 48.9 ± 13.5, 40.8 ± 12.2 | 6 | [23] |
Zhang (Jin-jin) et al. | 2020 | China | 58/82 | Cross-sectional | Severe/non-severe patients | 64 ± 15.5, 51.5 ± 13 | 6 | [22] |
Zheng (a) et al. | 2020 | China | 3/71 | Cross-sectional | Severe or critical)/non-severe | 67.875 ± 12.22, 44.845 ± 16.79 | 5 | [15] |
Zheng (b) et al. | 2020 | China | 3/9 | Cross-sectional | Severe or critical/Mild | 67.875 ± 12.22, 39.444 ± 14.32 | 5 | [15] |
Zheng (c) et al. | 2020 | China | 2/15 | Cross-sectional | Severe and critical/asymptomatic infected | 67.875 ± 12.22, 32.667 ± 22.68 | 5 | [15] |
Zhu et al. | 2020 | China | 43/71 | Retrospective cohort study | Severe group/non-severe group | 76 ± 6.67, 77 ± 8.15 | 8 | [25] |